Astrazeneca vs Novo Nordisk A S
Astrazeneca is the larger business, with $58.74bn of revenue in fiscal 2025 against $46.82bn for Novo Nordisk A S (1.3 times as much). Novo Nordisk A S grew faster (11.1% against 8.6%). Novo Nordisk A S kept more of each dollar of sales as profit: a net margin of 33.1% against 17.4%. Astrazeneca carries less debt relative to equity (60.9% against 136.1%).
| Latest fiscal year | AstrazenecaAZN, 2025 | Novo Nordisk A SNVO, 2025 |
|---|---|---|
| Revenue | $58.74bn | $46.82bn |
| Revenue growth | 8.6% | 11.1% |
| Net income | $10.22bn | $15.52bn |
| Operating margin | 23.4% | 41.3% |
| Net margin | 17.4% | 33.1% |
| Return on equity | 22.9% | 61.6% |
| Free cash flow | $11.77bn | $8.93bn |
| Cash | $5.71bn | $4.16bn |
| Total debt | $29.62bn | $41.49bn |
| Debt to equity | 60.9% | 136.1% |
| Dividend per share | — | — |
| Dividend yield | 1.7% | 4.4% |
| Share buybacks | $521m | $210m |
| Employees | — | — |
| Market value | $286.25bn | $177.65bn |
| Price vs our value range | Within our value range | Below our value range |
| Moat score | — | — |
| Insider trades, 12 months | 1 buys, 1 sales | 0 buys, 0 sales |